retatrutide fda approval timeline 2025 Commercial Availability Timeline: Key Milestones and Costs Retatrutide: What It Is &
Description
Results Fifty patients (82% female) were included
On average, patients remained on therapy for about 258 days before discontinuation, achieving roughly 10% total body weight loss before stopping
There isn't one
Obesity medicine is undergoing a massive shift, driven primarily by the clinical application of peptide therapy for weight loss.
.webp)
Additionally, we highlight the gaps for further studies in clinical applications of GLP-1 RAs in aging-related diseases
